

Summary

NFкB-p65 (phospho Ser529) Rabbit Polyclonal Antibody
Rabbit Polyclonal Antibody
Rabbit
IF,WB,IHC,ELISA
Human, Mouse, Rat, Monkey

Performance

Conjugation	Unconjugated
Modification	Phospho Antibody
lsotype	lgG
Clonality	Polyclonal
Form	Liquid
Storage	Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw
	cycles.
Buffer	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N.
Purification	Affinity purification

Immunogen

Gene Name	RELA
Alternative Names	RELA; NFKB3; Transcription factor p65; Nuclear factor NF-kappa-B p65 subunit; Nuclear
	factor of kappa light polypeptide gene enhancer in B-cells 3
Gene ID	5970.0
SwissProt ID	Q04206.Synthesized phospho-peptide around the phosphorylation site of human
	NFкB-p65 (phospho Ser529)

Application

Dilution Ratio	IF 1:50-200 WB 1:500 - 1:2000. IHC 1:100 - 1:300. ELISA: 1:20000. Not yet tested in other
	applications.

Product Name: NFκB-p65 (phospho Ser529) Rabbit Polyclonal Antibody Catalog #: APRab05103



Molecular Weight 60kD

Background

NF-kappa-B is a ubiquitous transcription factor involved in several biological processes. It is held in the cytoplasm in an inactive state by specific inhibitors. Upon degradation of the inhibitor, NF-kappa-B moves to the nucleus and activates transcription of specific genes. NF-kappa-B is composed of NFKB1 or NFKB2 bound to either REL, RELA, or RELB. The most abundant form of NF-kappa-B is NFKB1 complexed with the product of this gene, RELA. Four transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011], function:NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex.,PTM:Phosphorylation on 'Ser-536' stimulates acetylation on 'Lys-310' and interaction with CBP; the phosphorylated and acetylated forms show enhanced transcriptional activity., PTM: Reversibly acetylated; the acetylation seems to be mediated by CBP, the deacetylation by HDAC3. Acetylation at 'Lys-122' enhances DNA binding and impairs association with NFKBIA. Acetylation at 'Lys-310' is required for full transcriptional activity in the absence of effects on DNA binding and NFKBIA association. Acetylation can also lower DNAbinding and results in nuclear export., PTM: Ubiquitinated, leading to its proteosomal degradation. Degradation is required for termination of NF-kappa-B response., similarity: Contains 1 RHD (Rel-like) domain., subcellular location: Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B)., subunit: Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52 complex. May interact with ETHE1. Binds AES and TLE1. Interacts with TP53BP2. Binds to and is phosphorylated by the activated form of either RPS6KA4 or RPS6KA5. Interacts with ING4 and this interaction may be indirect. Interacts with CARM1, USP48 and UNC5CL. Interacts with IRAK1BP1 (By similarity).Interacts with




NFKBID (By similarity). Interacts with NFKBIA. Interacts with GSK3B. Interacts with NFKBIB (By similarity). Interacts with NFKBIZ (By similarity). Part of a 70-90 kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14. Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA. Interacts with HDAC1; the interaction requires non-phosphorylated RELA. Interacts with CBP; the interaction requires phosphorylated RELA. Interacts (phosphorylated at 'Thr-254') with PIN1; the interaction inhibits p65 binding to NFKBIA. Interacts with SOCS1. Interacts with UXT. Interacts with MTDH. Interacts with human respiratory syncytial virus (HRSV) protein M2-1.,


Research Area

MAPK_ERK_Growth;MAPK_G_Protein;Chemokine;Apoptosis_Inhibition;Apoptosis_Mitochondrial;Apoptosis_Overview;Toll_Like;NOD-like receptor;RIG-I-like receptor;Cytosolic DNA-sensing pathway;T_Cell_Receptor;B_Cell_Antigen;Neurotrophin;Adipocytokine;Epithelial cell signaling in Helicobacter pylori infection;Pathways in cancer;Pancreatic cancer;Prostate cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Small cell lung cancer;

Image Data




Enzyme-Linked Immunosorbent Assay (Phospho-ELISA) for Immunogen Phosphopeptide (Phospho-left) and Non-Phosphopeptide (Phospho-right), using NF-κB p65 (Phospho-Ser529) Antibody




Immunohistochemistry analysis of paraffin-embedded human breast cancer, using NF-κB p65 (Phospho-Ser529) Antibody. The picture on the right is blocked with the NF-κB p65 (Phospho-Ser529) peptide.






Immunofluorescence analysis of human-lung tissue. 1,NFκB-p65 (phospho Ser529) Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight) . 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min) .3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of human-lung tissue. 1,ΝFκB-p65 (phospho Ser529) Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight) . 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min) .3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of rat-heart tissue. 1,NFκB-p65 (phospho Ser529) Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight) . 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min) .3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B




Product Name: NFκB-p65 (phospho Ser529) Rabbit Polyclonal Antibody Catalog #: APRab05103



Immunofluorescence analysis of rat-heart tissue. 1,NFκB-p65 (phospho Ser529) Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight) . 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min) .3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B



Immunofluorescence analysis of mouse-spleen tissue. 1,ΝFκB-p65 (phospho Ser529) Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight) . 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min) .3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B



Immunofluorescence analysis of mouse-spleen tissue. 1,ΝFκB-p65 (phospho Ser529) Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight) . 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min) .3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B





Immunohistochemical analysis of paraffin-embedded Human-uterus tissue. 1,NFκB-p65 (phospho Ser529) Polyclonal Antibody was diluted at 1:200 (4°C,overnight) . 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C,20min) . 3,Secondary antibody was diluted at 1:200 (room tempeRature, 30min) . Negative control was used by secondary antibody only.

Note For research use only.